Press release
AngioConsult and Elucid Bio Announce Partnership Bringing an Innovative AI Technology into the European Market
Atherosclerosis, a condition of progressive narrowing and hardening of atrial walls due to plaque buildup, is the usual cause of heart attacks, strokes and peripheral vascular disease. Elucid’s software vascuCAP is the first-ever FDA and CE cleared, non-invasive technology to objectively measure all key characteristics of high-risk plaque. Its algorithms are uniquely validated by expert pathologists using a biobank of tissue specimens as an objective truth standard. In this way, the innovative solution only needs a single CT angiography to inform of risk of event, treatment selection, and, when appropriate, pre-procedure planning. It also enables longitudinal quantitation of plaque progression or regression to measure therapeutic response and changes to a patient’s risk profile.
“vascuCAP uses machine intelligence to analyze CT scans of coronary, carotid, and peripheral arteries to automatically quantify and classify the type of atherosclerotic plaque validated against histopathology. This information, along with key measures of the artery's structure, leads to significant improvements in event prediction accuracy compared to existing non-invasive diagnostics," states Blake Richards, CEO, Elucid Bio. “vascuCAP helps cardiologists, vascular surgeons, and radiologists make better treatment decisions."
“Ischemic heart disease and stroke are the two leading causes of death worldwide. vascuCAP is perfect proof that digital healthcare solutions are key to advancing patient care and the prediction of adverse cardiovascular events.”, states Benjamin Rieck, CEO, AngioConsult. “We are pleased to be the distributor to expand this technology throughout Europe and establish the brand in the market by raising awareness among key opinion leaders.”
AngioConsult GmbH
Heydenreichstr. 5
67346 Speyer
GERMANY
Press contact
Melanie Braun
info@angioconsult.de
About AngioConsult GmbH:
AngioConsult is Germany-based company specialized in the cardiovascular sector with three corporate branches: Healthcare IT, Business & Therapy Development, and Training & Innovation. In this way, AngioConsult addresses all challenges on the path from patent to commerce by combining product management, sales organization and training programs within one company. Website: www.angioconsult.de
About Elucid Bioimaging, Inc.:
Elucid Bio is a Boston-based medical technology company using AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with known or suspected cardiovascular disease. The company’s vascuCAP® software is the first tool to quantify atherosclerotic plaque against histology, deliver key arterial measures, and provide 3D visualization to inform risk of event: stroke or heart attack. vascuCAP’s unique information informs better treatment decisions by physicians, leading to better patient outcomes at a reduced cost of care. vascuCAP is available for commercial use in the U.S. and Europe. Website: www.elucidbio.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AngioConsult and Elucid Bio Announce Partnership Bringing an Innovative AI Technology into the European Market here
News-ID: 2130753 • Views: …
More Releases from AngioConsult GmbH
AngioConsult and Harrison Bay Life Sciences form unique partnership to defy chal …
Chattanooga/Speyer, October 14, 2020 – AngioConsult, a healthcare consultancy that has extensive experience in commercializing novel software technologies, announces a partnership with Harrison Bay Life Sciences (“HBLS”) to bring the new remote procedure support technology, ENVISIMED™, to the European market. HBLS is a medical device commercialization partner, bringing innovative medical products and services to the US-patient population. The two companies have the same mission and combine strengths to bring innovations…
AngioConsult strengthens the cooperation with Mitre Medical Corp. with the addit …
Speyer/Silicon Valley, 05/07/2018 – AngioConsult announces the strengthening of the cooperation with Mitre Medical Corp. with the addition of Andrew Kim to the team. Andrew is the second representative of AngioConsult supporting the medical device company, which is based in Silicon Valley, California. Benjamin Rieck, Sr Managing Partner of the healthcare consultancy with headquarters in Speyer, Germany, serves as a board member for Mitre Medical. Andrew brings great experience, having…
More Releases for Elucid
Medication Adherence Market Experience Some Large Growth In Near Future | McKess …
The growth of the Medication Adherence market can be attributed to the rising awareness about Medication Adherence due to growing programmes and initiatives organized with the aim to educate people about the significance of medical adherence. Moreover, factors like the ageing population, increment in the healthcare expenditure and pharmaceutical usage, and the surge in the prevalence of cardiovascular diseases are likely to propel the market growth over the forecast period..
The…
Smart Pill Boxes & Bottles Market | Medipense Inc., Medminder, Inc., MedReady, P …
Smart Pill Boxes & Bottles Market is expected to reach US$ 254.7 Mn in 2028, growing at a CAGR of 9.9% CAGR during the forecast period 2022-2028.
Sales of smart pill boxes and bottles are likely to reach around 800 thousand in 2019. According to a new analytical research study by Future Market Insights (FMI), smart pill boxes and bottles market will remain a high growth-low volume landscape over the course of next few years.…
mHealth Market Potential Growth, Share, Demand and Analysis of Key Players- Rese …
Growing adoption of smartphones is driving mHealth market growth
Market Overview:
mHealth is used for collection of clinical health data and delivery of healthcare information to medical personnel to real time monitoring of the patient by provision of direct care.
Competitive Landscape:
Medtronic Inc., Apple Inc., Sanofi, Mobistante, Inc., AirStrip Technologies, Inc., AliveCor, Inc., LifeWatch AG, Koninklijke Philips N.V, Jawbone, Nike, Inc., Omron Corporation, Johnson and Johnson, Bio Telemetry Inc., Withings, AgaMatrix Inc., iHealth…
mHealth Market – Insights on Key Players Positioning and Evolution of New Play …
mHealth Market report studies the mHealth with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete mHealth Market analysis segmented by companies, region, type and applications in the report.
Scope of mHealth: mHealth Market report evaluates the growth rate and the market value based…
Bio-Imaging Technology Market Size, Competitive Analysis, Share, Forecast- 2019- …
The global bio-imaging technology market is expected to register substantial growth rate over the forecast period. Bio-imaging refers to the production of images of living organisms by magnetic resonance imaging, ultrasound, X-rays, and more for diagnosis of diseases or research purposes.
Among the segment, medical imaging seems to be the most promising ones in the bio-imaging technology industry. It utilizes processes and techniques to produce images of anatomical areas of the…
Bio-Imaging Technology Market Trends, Size, Competitive Analysis and Forecast - …
Bio-imaging technology market is expected to grow at a considerable rate during the forecast period 2019-2025. Bio-imaging refers to a non-invasive procedure that visualizes biological processes in real-time. These technologies enable the diagnosis of the disease such as cancer and provide a database of physiology and anatomy for future study. The global bio-imaging technology market is influenced by the rising geriatric population across the globe coupled with the increasing prevalence…
